**Supplementary Table 1.** **Correlation between TMCO3 expression and clinicopathological factors in the TCGA cohort**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Category** | **Subcategory** | **TCGA-cohort (*n*=370)** | | | |
| **Count** | **Low** | **High** | ***p*** |
| Sex | Female | 121 | 44 (36.4%) | 77 (63.6%) | <0.001 |
|  | Male | 249 | 141 (56.6%) | 108 (43.4%) |  |
| Age, years | ≤50 | 78 | 35 (44.9%) | 43 (55.1%) | 0.308 |
|  | >50 | 292 | 150 (51.4%) | 142 (48.6%) |  |
| Pathological grade | G1-2 | 232 | 127 (54.7%) | 105 (45.3%) | 0.061 |
|  | G3-4 | 133 | 56 (42.1%) | 77 (57.9%) |  |
|  | Unknown | 5 | 2 (40.0%) | 3 (60.0%) |  |
| Clinical stage | I-II | 256 | 138 (53.9%) | 118 (46.1%) | 0.054 |
|  | III-IV | 90 | 39 (43.3%) | 51 (56.7%) |  |
|  | Unknown | 24 | 8 (33.3%) | 16 (66.7%) |  |